Multiple Sclerosis
Conditions
Brief summary
The primary objectives of this study is to examine the efficacy of the Unified Protocol in decreasing depression and anxiety among individuals with MS and the secondary outcomes (e.g., improved well-being, QOL, coping, etc.) that may occur in tandem.
Detailed description
The primary objectives of this study is to examine the efficacy of the Unified Protocol in decreasing depression and anxiety among individuals with MS and the secondary outcomes (e.g., improved well-being, QOL, coping, etc.) that may occur in tandem. To achieve this, the investigation has the following specific aims: Specific Aim 1: Conduct a pilot Randomized Controlled Trial (RCT) of the Unified Protocol among individuals with MS to determine the effectiveness of the intervention in reducing depression and anxiety. Hypothesis 1: Individuals who participate in the Unified Protocol intervention will report a decrease in their depression and anxiety compared to individuals in the control group. Specific Aim 2: Conduct a pilot RCT of the Unified Protocol among individuals with MS to determine the effectiveness of the intervention in improving secondary outcomes of psychological well-being, QOL, coping, and MS symptomatology over time. Hypothesis 2: Individuals who participate in the Unified Protocol intervention will report an increase in psychological well-being, QOL, coping, and MS symptomatology over time compared to participants in the control group.
Interventions
BEHAVIORALUnified Protocol
The Unified Protocol is a transdiagnostic intervention developed to treat depression and anxiety.
Sponsors
Kessler Foundation
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)
Masking description
The assessor is blinded to the group assignment
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Diagnosis of multiple sclerosis * 18 years of age or older * Experiencing significant depression and/or anxiety * English-speaking * Able to provide informed consent * Access to the internet
Exclusion criteria
* History of any other neurological illness (e.g. traumatic brain injury, epilepsy, dementia) * Current participation in another randomized controlled trial * Cognitive impairment that would affect my ability to fully participate in the group * Unable to attend group sessions * Active participation in another formal clinical group or psychological therapy * Any other medical or psychological condition that, in the judgement of the investigators, prevents successful participation in the study
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Hospital Anxiety and Depression Scale (HADS) - Change in Depression | Baseline, 12 weeks, 24 weeks | Self-report measure of depression. Scores range from 0-21 with higher scores indicating greater depression. |
| Hospital Anxiety and Depression Scale (HADS) - Change in Anxiety | Baseline, 12 weeks, 24 weeks | Self-report measure of anxiety. Scores range from 0-21 with higher scores indicating greater anxiety. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Satisfaction with Life Scale (SWLS) - Changes in Quality of Life | Baseline, 12 weeks, 24 weeks | Self-report measure of quality of life and satisfaction. Scores range from 5-35 with higher scores indicating greater life satisfaction. |
| MOS Pain Effects Scale (PES) - Change in Pain | Baseline, 12 weeks, 24 weeks | Self-report measure of pain. Scores range from 0-30 with higher scores indicating greater pain. |
| General Self-Efficacy Scale (GSES) - Change in Self-efficacy | Baseline, 12 weeks, 24 weeks | Self-report measure of self-efficacy. Scores range from 10-40 with higher scores indicating greater self-efficacy. |
| University of Washington Self-Efficacy Scale - Change in MS specific self-efficacy | Baseline, 12 weeks, 24 weeks | Self-report measure of disease self-efficacy. Scores range from 0-100 (T-scores) with higher scores indicating greater self-efficacy. |
| Modified Fatigue Impact Scale (MFIS) - Change in Fatigue | Baseline, 12 weeks, 24 weeks | Self-report measure of fatigue. Scores range from 0-84 with higher scores indicating greater fatigue. |
| COPE inventory - Change in Coping | Baseline, 12 weeks, 24 weeks | Self-report measure of coping. Scores range from 4-16 for each coping scale with higher scores indicating greater coping. |
| Benefit Finding in Multiple Sclerosis (BFIMS) - Change in Benefit-finding | Baseline, 12 weeks, 24 weeks | Self-report measure of positive coping. Scores range from 43-129 for the total scale with higher scores indicating greater benefit-finding. |
| Flourishing Scale (FS) - Change in Quality of Life | Baseline, 12 weeks, 24 weeks | Self-report measure of quality of life. Scores range from 8-56 with higher scores indicating greater quality of life. |
| Ryff Psychological Well-being Scales (RYFFPWB) - Changes in well-being | Baseline, 12 weeks, 24 weeks | Self-report measure of psychological well-being. Scores range from 14-84 for each subscale with higher scores indicating greater psychological well-being. |
| University of Washington Resilience Scale - Change in Resilience | Baseline, 12 weeks, 24 weeks | Self-report measure of resilience. Scores range from 8-40 with higher scores indicating greater resilience. |
| Pittsburgh Sleep Quality Index (PQSI) - Change in Sleep | Baseline, 12 weeks, 24 weeks | Self-report measure of sleep. Scores range from 0-21 with higher scores indicating greater sleep problems. |
Countries
United States
Contacts
Primary ContactBelinda L Washington, BA
Backup ContactLauren B Strober, PhD
Outcome results
None listed